Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Viale, Giuseppe"" wg kryterium: Autor


Tytuł :
Expression of tumor-associated antigens in breast cancer subtypes.
Autorzy :
Curigliano G; Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy. Electronic address: giuseppe..
Bagnardi V; Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy.
Ghioni M; Division of Pathology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Louahed J; GSK, USA.
Brichard V; GSK, USA; Vianova-Biosciences, Belgium.
Lehmann FF; GSK, USA; Celyad, Mont-Saint-Guibert, Belgium.
Marra A; Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy.
Trapani D; Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy.
Criscitiello C; Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Viale G; Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy; Division of Pathology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Pokaż więcej
Źródło :
Breast (Edinburgh, Scotland) [Breast] 2020 Feb; Vol. 49, pp. 202-209. Date of Electronic Publication: 2019 Dec 12.
Typ publikacji :
Journal Article
MeSH Terms :
Antigens, Neoplasm/*analysis
Breast Neoplasms/*immunology
Membrane Proteins/*analysis
Receptor, ErbB-2/*analysis
WT1 Proteins/*analysis
Adult ; Aged ; Biomarkers, Tumor/analysis ; Female ; Humans ; Immunohistochemistry ; Middle Aged ; Receptors, Estrogen/metabolism ; Receptors, Progesterone/metabolism ; Triple Negative Breast Neoplasms/metabolism
Czasopismo naukowe
Tytuł :
Treatment selection for patients with equivocal HER2 status and in luminal versus HER2-enriched disease.
Autorzy :
Viale G; University of Milan, Department of Oncology and Hemato-Oncology, Milan, Italy; Department of Pathology and Laboratory Medicine IEO, European Institute of Oncology IRCCS, Milan, Italy. Electronic address: giuseppe.viale@ieo.it.
Munzone E; Division of Medical Senology IEO, European Institute of Oncology IRCCS, Milan, Italy.
Pokaż więcej
Źródło :
Breast (Edinburgh, Scotland) [Breast] 2019 Nov; Vol. 48 Suppl 1, pp. S49-S52.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents, Immunological/*therapeutic use
B7-H1 Antigen/*therapeutic use
Breast Neoplasms/*drug therapy
Breast Neoplasms/*immunology
Programmed Cell Death 1 Receptor/*therapeutic use
Receptor, ErbB-2/*immunology
Female ; Humans ; Patient Selection ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial.
Autorzy :
Lambertini M; Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genova, Italy. .; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy. .
Campbell C; Frontier Science, Kingussie, UK.
Gelber RD; Dana-Farber Cancer Institute, Harvard Medical School, Harvard TH Chan School of Public Health and Frontier Science and Technology Research Foundation, Boston, MA, USA.
Viale G; IEO, European Institute of Oncology IRCCS, University of Milan, Milan, Italy.
McCullough A; Mayo Clinic, Phoenix, AZ, USA.
Hilbers F; Breast International Group, Brussels, Belgium.
Korde LA; National Cancer Institute, Bethesda, MD, USA.
Werner O; Novartis Pharma AG, Basel, Switzerland.
Chumsri S; Mayo Clinic, Jacksonville, FL, USA.
Jackisch C; Sana Klinikum Offenbach, Offenbach, Germany.
Wolff AC; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
Vaz-Luis I; Institut Gustave Roussy, Villejuif, France.
Ferreira AR; Champalimaud Clinical Center, Champalimaud Foundation and Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Prat A; Department of Medical Oncology, Hospital Clínic of Barcelona, Barcelona, Spain.
Moreno-Aspitia A; Mayo Clinic, Jacksonville, FL, USA.
Piccart M; Institut Jules Bordet and Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.
Loi S; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia.
de Azambuja E; Institut Jules Bordet and Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.
Pokaż więcej
Źródło :
Breast cancer research and treatment [Breast Cancer Res Treat] 2019 Aug; Vol. 177 (1), pp. 103-114. Date of Electronic Publication: 2019 May 27.
Typ publikacji :
Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Breast Neoplasms/*metabolism
Breast Neoplasms/*therapy
Receptor, ErbB-2/*metabolism
Receptors, Progesterone/*metabolism
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Breast Neoplasms/diagnosis ; Breast Neoplasms/mortality ; Chemotherapy, Adjuvant ; Disease-Free Survival ; Female ; Humans ; Molecular Targeted Therapy ; Proportional Hazards Models ; Receptor, ErbB-2/antagonists & inhibitors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
Autorzy :
Loi S; Division of Research and Clinical Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia. Electronic address: .
Giobbie-Hurder A; IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Gombos A; Institute Jules Bordet, Brussels, Belgium.
Bachelot T; Centre Léon Bérard, Lyon, France.
Hui R; Westmead Hospital and the University of Sydney, Sydney, NSW, Australia.
Curigliano G; University of Milano, Milan, Italy; IEO, European Institute of Oncology IRCCS, Milan, Italy.
Campone M; Institut de Cancérologie de l'Ouest, Saint-Herblain, Nantes, France.
Biganzoli L; Ospedale di Prato-AUSL Toscana Centro, Prato, Italy.
Bonnefoi H; Institut Bergonié Comprehensive Cancer Center, Université de Bordeaux, Bordeaux, France.
Jerusalem G; International Breast Cancer Study Group, CHU Liège, Liège University, Liège, Belgium.
Bartsch R; Medical University of Vienna, Vienna, Austria.
Rabaglio-Poretti M; University Hospital Inselspital, Bern, Switzerland; International Breast Cancer Study Group Coordinating Center, Bern, Switzerland.
Kammler R; International Breast Cancer Study Group Coordinating Center, Bern, Switzerland; International Breast Cancer Study Group and Central Pathology Office, Bern, Switzerland.
Maibach R; International Breast Cancer Study Group Coordinating Center, Bern, Switzerland.
Smyth MJ; QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
Di Leo A; International Breast Cancer Study Group and Ospedale di Prato-AUSL Toscana Centro, Prato, Italy.
Colleoni M; International Breast Cancer Study Group and Division of Medical Senology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Viale G; University of Milano, Milan, Italy; IEO, European Institute of Oncology IRCCS, Milan, Italy; International Breast Cancer Study Group and Central Pathology Office, Bern, Switzerland.
Regan MM; IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
André F; Institut Gustave Roussy, Université Paris Sud, INSERM U981, Villejuif, France.
Pokaż więcej
Corporate Authors :
International Breast Cancer Study Group and the Breast International Group
Źródło :
The Lancet. Oncology [Lancet Oncol] 2019 Mar; Vol. 20 (3), pp. 371-382. Date of Electronic Publication: 2019 Feb 11.
Typ publikacji :
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms :
Antibodies, Monoclonal, Humanized/*administration & dosage
Breast Neoplasms/*drug therapy
Receptor, ErbB-2/*genetics
Trastuzumab/*administration & dosage
Adolescent ; Adult ; Aged ; B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/genetics ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Dose-Response Relationship, Drug ; Drug Resistance, Neoplasm/drug effects ; Female ; Humans ; Middle Aged ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/genetics ; Trastuzumab/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
Autorzy :
Wolff AC; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland; Lisa M. McShane, National Cancer Institute, Bethesda, Maryland; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City; Kimberly H. Allison, Stanford University School of Medicine, Stanford, California; Patrick Fitzgibbons, St Jude Medical Center, Fullerton, California; Michael F. Press, University of Southern California, Los Angeles; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, Virginia; John M.S. Bartlett, Ontario Institute for Cancer Research, Toronto, Ontario, Canada; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, Australia; Ian O. Ellis, The University of Nottingham, Nottingham, United Kingdom; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, Minnesota; Patricia A. Spears, Cancer Information and Support Network, Raleigh, North Carolina; Gail H. Vance, Indiana University School of Medicine, Indianapolis; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Hammond MEH; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland; Lisa M. McShane, National Cancer Institute, Bethesda, Maryland; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City; Kimberly H. Allison, Stanford University School of Medicine, Stanford, California; Patrick Fitzgibbons, St Jude Medical Center, Fullerton, California; Michael F. Press, University of Southern California, Los Angeles; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, Virginia; John M.S. Bartlett, Ontario Institute for Cancer Research, Toronto, Ontario, Canada; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, Australia; Ian O. Ellis, The University of Nottingham, Nottingham, United Kingdom; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, Minnesota; Patricia A. Spears, Cancer Information and Support Network, Raleigh, North Carolina; Gail H. Vance, Indiana University School of Medicine, Indianapolis; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Allison KH; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland; Lisa M. McShane, National Cancer Institute, Bethesda, Maryland; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City; Kimberly H. Allison, Stanford University School of Medicine, Stanford, California; Patrick Fitzgibbons, St Jude Medical Center, Fullerton, California; Michael F. Press, University of Southern California, Los Angeles; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, Virginia; John M.S. Bartlett, Ontario Institute for Cancer Research, Toronto, Ontario, Canada; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, Australia; Ian O. Ellis, The University of Nottingham, Nottingham, United Kingdom; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, Minnesota; Patricia A. Spears, Cancer Information and Support Network, Raleigh, North Carolina; Gail H. Vance, Indiana University School of Medicine, Indianapolis; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Harvey BE; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland; Lisa M. McShane, National Cancer Institute, Bethesda, Maryland; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City; Kimberly H. Allison, Stanford University School of Medicine, Stanford, California; Patrick Fitzgibbons, St Jude Medical Center, Fullerton, California; Michael F. Press, University of Southern California, Los Angeles; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, Virginia; John M.S. Bartlett, Ontario Institute for Cancer Research, Toronto, Ontario, Canada; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, Australia; Ian O. Ellis, The University of Nottingham, Nottingham, United Kingdom; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, Minnesota; Patricia A. Spears, Cancer Information and Support Network, Raleigh, North Carolina; Gail H. Vance, Indiana University School of Medicine, Indianapolis; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Mangu PB; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland; Lisa M. McShane, National Cancer Institute, Bethesda, Maryland; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City; Kimberly H. Allison, Stanford University School of Medicine, Stanford, California; Patrick Fitzgibbons, St Jude Medical Center, Fullerton, California; Michael F. Press, University of Southern California, Los Angeles; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, Virginia; John M.S. Bartlett, Ontario Institute for Cancer Research, Toronto, Ontario, Canada; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, Australia; Ian O. Ellis, The University of Nottingham, Nottingham, United Kingdom; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, Minnesota; Patricia A. Spears, Cancer Information and Support Network, Raleigh, North Carolina; Gail H. Vance, Indiana University School of Medicine, Indianapolis; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Bartlett JMS; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland; Lisa M. McShane, National Cancer Institute, Bethesda, Maryland; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City; Kimberly H. Allison, Stanford University School of Medicine, Stanford, California; Patrick Fitzgibbons, St Jude Medical Center, Fullerton, California; Michael F. Press, University of Southern California, Los Angeles; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, Virginia; John M.S. Bartlett, Ontario Institute for Cancer Research, Toronto, Ontario, Canada; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, Australia; Ian O. Ellis, The University of Nottingham, Nottingham, United Kingdom; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, Minnesota; Patricia A. Spears, Cancer Information and Support Network, Raleigh, North Carolina; Gail H. Vance, Indiana University School of Medicine, Indianapolis; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Bilous M; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland; Lisa M. McShane, National Cancer Institute, Bethesda, Maryland; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City; Kimberly H. Allison, Stanford University School of Medicine, Stanford, California; Patrick Fitzgibbons, St Jude Medical Center, Fullerton, California; Michael F. Press, University of Southern California, Los Angeles; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, Virginia; John M.S. Bartlett, Ontario Institute for Cancer Research, Toronto, Ontario, Canada; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, Australia; Ian O. Ellis, The University of Nottingham, Nottingham, United Kingdom; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, Minnesota; Patricia A. Spears, Cancer Information and Support Network, Raleigh, North Carolina; Gail H. Vance, Indiana University School of Medicine, Indianapolis; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Ellis IO; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland; Lisa M. McShane, National Cancer Institute, Bethesda, Maryland; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City; Kimberly H. Allison, Stanford University School of Medicine, Stanford, California; Patrick Fitzgibbons, St Jude Medical Center, Fullerton, California; Michael F. Press, University of Southern California, Los Angeles; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, Virginia; John M.S. Bartlett, Ontario Institute for Cancer Research, Toronto, Ontario, Canada; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, Australia; Ian O. Ellis, The University of Nottingham, Nottingham, United Kingdom; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, Minnesota; Patricia A. Spears, Cancer Information and Support Network, Raleigh, North Carolina; Gail H. Vance, Indiana University School of Medicine, Indianapolis; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Fitzgibbons P; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland; Lisa M. McShane, National Cancer Institute, Bethesda, Maryland; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City; Kimberly H. Allison, Stanford University School of Medicine, Stanford, California; Patrick Fitzgibbons, St Jude Medical Center, Fullerton, California; Michael F. Press, University of Southern California, Los Angeles; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, Virginia; John M.S. Bartlett, Ontario Institute for Cancer Research, Toronto, Ontario, Canada; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, Australia; Ian O. Ellis, The University of Nottingham, Nottingham, United Kingdom; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, Minnesota; Patricia A. Spears, Cancer Information and Support Network, Raleigh, North Carolina; Gail H. Vance, Indiana University School of Medicine, Indianapolis; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Hanna W; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland; Lisa M. McShane, National Cancer Institute, Bethesda, Maryland; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City; Kimberly H. Allison, Stanford University School of Medicine, Stanford, California; Patrick Fitzgibbons, St Jude Medical Center, Fullerton, California; Michael F. Press, University of Southern California, Los Angeles; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, Virginia; John M.S. Bartlett, Ontario Institute for Cancer Research, Toronto, Ontario, Canada; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, Australia; Ian O. Ellis, The University of Nottingham, Nottingham, United Kingdom; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, Minnesota; Patricia A. Spears, Cancer Information and Support Network, Raleigh, North Carolina; Gail H. Vance, Indiana University School of Medicine, Indianapolis; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Jenkins RB; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland; Lisa M. McShane, National Cancer Institute, Bethesda, Maryland; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City; Kimberly H. Allison, Stanford University School of Medicine, Stanford, California; Patrick Fitzgibbons, St Jude Medical Center, Fullerton, California; Michael F. Press, University of Southern California, Los Angeles; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, Virginia; John M.S. Bartlett, Ontario Institute for Cancer Research, Toronto, Ontario, Canada; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, Australia; Ian O. Ellis, The University of Nottingham, Nottingham, United Kingdom; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, Minnesota; Patricia A. Spears, Cancer Information and Support Network, Raleigh, North Carolina; Gail H. Vance, Indiana University School of Medicine, Indianapolis; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Press MF; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland; Lisa M. McShane, National Cancer Institute, Bethesda, Maryland; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City; Kimberly H. Allison, Stanford University School of Medicine, Stanford, California; Patrick Fitzgibbons, St Jude Medical Center, Fullerton, California; Michael F. Press, University of Southern California, Los Angeles; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, Virginia; John M.S. Bartlett, Ontario Institute for Cancer Research, Toronto, Ontario, Canada; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, Australia; Ian O. Ellis, The University of Nottingham, Nottingham, United Kingdom; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, Minnesota; Patricia A. Spears, Cancer Information and Support Network, Raleigh, North Carolina; Gail H. Vance, Indiana University School of Medicine, Indianapolis; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Spears PA; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland; Lisa M. McShane, National Cancer Institute, Bethesda, Maryland; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City; Kimberly H. Allison, Stanford University School of Medicine, Stanford, California; Patrick Fitzgibbons, St Jude Medical Center, Fullerton, California; Michael F. Press, University of Southern California, Los Angeles; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, Virginia; John M.S. Bartlett, Ontario Institute for Cancer Research, Toronto, Ontario, Canada; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, Australia; Ian O. Ellis, The University of Nottingham, Nottingham, United Kingdom; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, Minnesota; Patricia A. Spears, Cancer Information and Support Network, Raleigh, North Carolina; Gail H. Vance, Indiana University School of Medicine, Indianapolis; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Vance GH; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland; Lisa M. McShane, National Cancer Institute, Bethesda, Maryland; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City; Kimberly H. Allison, Stanford University School of Medicine, Stanford, California; Patrick Fitzgibbons, St Jude Medical Center, Fullerton, California; Michael F. Press, University of Southern California, Los Angeles; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, Virginia; John M.S. Bartlett, Ontario Institute for Cancer Research, Toronto, Ontario, Canada; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, Australia; Ian O. Ellis, The University of Nottingham, Nottingham, United Kingdom; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, Minnesota; Patricia A. Spears, Cancer Information and Support Network, Raleigh, North Carolina; Gail H. Vance, Indiana University School of Medicine, Indianapolis; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Viale G; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland; Lisa M. McShane, National Cancer Institute, Bethesda, Maryland; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City; Kimberly H. Allison, Stanford University School of Medicine, Stanford, California; Patrick Fitzgibbons, St Jude Medical Center, Fullerton, California; Michael F. Press, University of Southern California, Los Angeles; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, Virginia; John M.S. Bartlett, Ontario Institute for Cancer Research, Toronto, Ontario, Canada; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, Australia; Ian O. Ellis, The University of Nottingham, Nottingham, United Kingdom; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, Minnesota; Patricia A. Spears, Cancer Information and Support Network, Raleigh, North Carolina; Gail H. Vance, Indiana University School of Medicine, Indianapolis; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
McShane LM; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland; Lisa M. McShane, National Cancer Institute, Bethesda, Maryland; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City; Kimberly H. Allison, Stanford University School of Medicine, Stanford, California; Patrick Fitzgibbons, St Jude Medical Center, Fullerton, California; Michael F. Press, University of Southern California, Los Angeles; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, Virginia; John M.S. Bartlett, Ontario Institute for Cancer Research, Toronto, Ontario, Canada; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, Australia; Ian O. Ellis, The University of Nottingham, Nottingham, United Kingdom; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, Minnesota; Patricia A. Spears, Cancer Information and Support Network, Raleigh, North Carolina; Gail H. Vance, Indiana University School of Medicine, Indianapolis; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Dowsett M; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland; Lisa M. McShane, National Cancer Institute, Bethesda, Maryland; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City; Kimberly H. Allison, Stanford University School of Medicine, Stanford, California; Patrick Fitzgibbons, St Jude Medical Center, Fullerton, California; Michael F. Press, University of Southern California, Los Angeles; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, Virginia; John M.S. Bartlett, Ontario Institute for Cancer Research, Toronto, Ontario, Canada; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, Australia; Ian O. Ellis, The University of Nottingham, Nottingham, United Kingdom; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, Minnesota; Patricia A. Spears, Cancer Information and Support Network, Raleigh, North Carolina; Gail H. Vance, Indiana University School of Medicine, Indianapolis; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Pokaż więcej
Źródło :
Archives of pathology & laboratory medicine [Arch Pathol Lab Med] 2018 Nov; Vol. 142 (11), pp. 1364-1382. Date of Electronic Publication: 2018 May 30.
Typ publikacji :
Journal Article; Practice Guideline
MeSH Terms :
Breast Neoplasms*
Biomarkers, Tumor/*analysis
Medical Oncology/*standards
Receptor, ErbB-2/*analysis
Female ; Humans ; Immunohistochemistry/methods ; Immunohistochemistry/standards ; In Situ Hybridization/methods ; In Situ Hybridization/standards ; Medical Oncology/methods ; United States
Czasopismo naukowe
Tytuł :
The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment.
Autorzy :
Marchiò C; Departments of Medical Sciences.; Pathology-Genetics-Immunology Department, Institut Curie, Paris.
Dell'Orto P; Pathology Department, European Institute of Oncology.
Annaratone L; Departments of Medical Sciences.
Geyer FC; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.
Venesio T; Candiolo Cancer Institute-FPO-IRCCS.
Berrino E; Candiolo Cancer Institute-FPO-IRCCS.
Verdun di Cantogno L; Pathology Unit.
Garofoli A; Institute of Pathology, University Hospital Basel, Basel, Switzerland.
Rangel N; Departments of Medical Sciences.; Natural and Mathematical Sciences Faculty, University of the Rosario, Bogotá, Colombia.
Casorzo L; Candiolo Cancer Institute-FPO-IRCCS.
dell'Aglio C; Candiolo Cancer Institute-FPO-IRCCS.
Gugliotta P; Departments of Medical Sciences.
Trisolini E; Departments of Medical Sciences.
Beano A; Oncology Unit, University Hospital Città della Salute e della Scienza di Torino.
Pietribiasi F; Pathology Division, Santa Croce Hospital, Moncalieri.
Orlassino R; Department of Pathology, Ivrea Community Hospital (A.S.L. TO4), Turin, Italy.
Cassoni P; Departments of Medical Sciences.
Pich A; Molecular Biotechnology and Health Sciences.
Montemurro F; Investigative Clinical Oncology, FPO-Candiolo Cancer Institute (IRCCS), Candiolo.
Mottolese M; Department of Pathology, Regina Elena National Cancer Institute, Rome, Italy.
Vincent-Salomon A; Pathology-Genetics-Immunology Department, Institut Curie, Paris.
Penault-Llorca F; Jean Perrin Center, Clermont-Ferrand France and UMRINSERM U1240, University of Auvergne, Clermont-Ferrand, France.
Medico E; Candiolo Cancer Institute-FPO-IRCCS.; Oncology, University of Turin, Turin.
Ng CKY; Institute of Pathology, University Hospital Basel, Basel, Switzerland.
Viale G; Pathology Department, European Institute of Oncology.; Department of Oncology and Oncohematology, University of Milan, Milan.
Sapino A; Departments of Medical Sciences.; Candiolo Cancer Institute-FPO-IRCCS.
Pokaż więcej
Źródło :
The American journal of surgical pathology [Am J Surg Pathol] 2018 Sep; Vol. 42 (9), pp. 1190-1200.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Biomarkers, Tumor/*analysis
Breast Neoplasms/*genetics
Breast Neoplasms/*pathology
Carcinoma/*genetics
Carcinoma/*pathology
Receptor, ErbB-2/*genetics
Adult ; Biomarkers, Tumor/genetics ; Female ; Gene Expression Profiling ; Humans ; Middle Aged
Czasopismo naukowe
Tytuł :
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
Autorzy :
Wolff AC; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City, UT; Kimberly H. Allison, Stanford University School of Medicine, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, New South Wales, Australia; Ian O. Ellis, The University of Nottingham, Nottingham; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Patricia A. Spears, Cancer Information and Support Network, Raleigh, NC; Gail H. Vance, Indiana University School of Medicine, Indianapolis, IN; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Hammond MEH; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City, UT; Kimberly H. Allison, Stanford University School of Medicine, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, New South Wales, Australia; Ian O. Ellis, The University of Nottingham, Nottingham; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Patricia A. Spears, Cancer Information and Support Network, Raleigh, NC; Gail H. Vance, Indiana University School of Medicine, Indianapolis, IN; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Allison KH; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City, UT; Kimberly H. Allison, Stanford University School of Medicine, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, New South Wales, Australia; Ian O. Ellis, The University of Nottingham, Nottingham; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Patricia A. Spears, Cancer Information and Support Network, Raleigh, NC; Gail H. Vance, Indiana University School of Medicine, Indianapolis, IN; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Harvey BE; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City, UT; Kimberly H. Allison, Stanford University School of Medicine, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, New South Wales, Australia; Ian O. Ellis, The University of Nottingham, Nottingham; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Patricia A. Spears, Cancer Information and Support Network, Raleigh, NC; Gail H. Vance, Indiana University School of Medicine, Indianapolis, IN; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Mangu PB; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City, UT; Kimberly H. Allison, Stanford University School of Medicine, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, New South Wales, Australia; Ian O. Ellis, The University of Nottingham, Nottingham; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Patricia A. Spears, Cancer Information and Support Network, Raleigh, NC; Gail H. Vance, Indiana University School of Medicine, Indianapolis, IN; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Bartlett JMS; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City, UT; Kimberly H. Allison, Stanford University School of Medicine, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, New South Wales, Australia; Ian O. Ellis, The University of Nottingham, Nottingham; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Patricia A. Spears, Cancer Information and Support Network, Raleigh, NC; Gail H. Vance, Indiana University School of Medicine, Indianapolis, IN; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Bilous M; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City, UT; Kimberly H. Allison, Stanford University School of Medicine, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, New South Wales, Australia; Ian O. Ellis, The University of Nottingham, Nottingham; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Patricia A. Spears, Cancer Information and Support Network, Raleigh, NC; Gail H. Vance, Indiana University School of Medicine, Indianapolis, IN; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Ellis IO; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City, UT; Kimberly H. Allison, Stanford University School of Medicine, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, New South Wales, Australia; Ian O. Ellis, The University of Nottingham, Nottingham; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Patricia A. Spears, Cancer Information and Support Network, Raleigh, NC; Gail H. Vance, Indiana University School of Medicine, Indianapolis, IN; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Fitzgibbons P; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City, UT; Kimberly H. Allison, Stanford University School of Medicine, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, New South Wales, Australia; Ian O. Ellis, The University of Nottingham, Nottingham; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Patricia A. Spears, Cancer Information and Support Network, Raleigh, NC; Gail H. Vance, Indiana University School of Medicine, Indianapolis, IN; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Hanna W; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City, UT; Kimberly H. Allison, Stanford University School of Medicine, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, New South Wales, Australia; Ian O. Ellis, The University of Nottingham, Nottingham; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Patricia A. Spears, Cancer Information and Support Network, Raleigh, NC; Gail H. Vance, Indiana University School of Medicine, Indianapolis, IN; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Jenkins RB; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City, UT; Kimberly H. Allison, Stanford University School of Medicine, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, New South Wales, Australia; Ian O. Ellis, The University of Nottingham, Nottingham; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Patricia A. Spears, Cancer Information and Support Network, Raleigh, NC; Gail H. Vance, Indiana University School of Medicine, Indianapolis, IN; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Press MF; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City, UT; Kimberly H. Allison, Stanford University School of Medicine, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, New South Wales, Australia; Ian O. Ellis, The University of Nottingham, Nottingham; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Patricia A. Spears, Cancer Information and Support Network, Raleigh, NC; Gail H. Vance, Indiana University School of Medicine, Indianapolis, IN; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Spears PA; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City, UT; Kimberly H. Allison, Stanford University School of Medicine, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, New South Wales, Australia; Ian O. Ellis, The University of Nottingham, Nottingham; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Patricia A. Spears, Cancer Information and Support Network, Raleigh, NC; Gail H. Vance, Indiana University School of Medicine, Indianapolis, IN; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Vance GH; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City, UT; Kimberly H. Allison, Stanford University School of Medicine, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, New South Wales, Australia; Ian O. Ellis, The University of Nottingham, Nottingham; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Patricia A. Spears, Cancer Information and Support Network, Raleigh, NC; Gail H. Vance, Indiana University School of Medicine, Indianapolis, IN; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Viale G; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City, UT; Kimberly H. Allison, Stanford University School of Medicine, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, New South Wales, Australia; Ian O. Ellis, The University of Nottingham, Nottingham; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Patricia A. Spears, Cancer Information and Support Network, Raleigh, NC; Gail H. Vance, Indiana University School of Medicine, Indianapolis, IN; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
McShane LM; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City, UT; Kimberly H. Allison, Stanford University School of Medicine, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, New South Wales, Australia; Ian O. Ellis, The University of Nottingham, Nottingham; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Patricia A. Spears, Cancer Information and Support Network, Raleigh, NC; Gail H. Vance, Indiana University School of Medicine, Indianapolis, IN; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Dowsett M; Antonio C. Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore; Lisa M. McShane, National Cancer Institute, Bethesda, MD; M. Elizabeth Hale Hammond, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City, UT; Kimberly H. Allison, Stanford University School of Medicine, Stanford; Patrick Fitzgibbons, St Jude Medical Center, Fullerton; Michael F. Press, University of Southern California, Los Angeles, CA; Brittany E. Harvey and Pamela B. Mangu, American Society of Clinical Oncology, Alexandria, VA; John M.S. Bartlett, Ontario Institute for Cancer Research; Wedad Hanna, Sunnybrook Health Sciences Centre and Women's College Hospital, Toronto, Ontario, Canada; Michael Bilous, Western Sydney University and Australian Clinical Laboratories, Sydney, New South Wales, Australia; Ian O. Ellis, The University of Nottingham, Nottingham; Mitchell Dowsett, The Royal Marsden NHS Foundation Trust, London, United Kingdom; Robert B. Jenkins, Mayo Clinic, Rochester, MN; Patricia A. Spears, Cancer Information and Support Network, Raleigh, NC; Gail H. Vance, Indiana University School of Medicine, Indianapolis, IN; and Giuseppe Viale, University of Milan and Istituto Europeo di Oncologia, Milan, Italy.
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2018 Jul 10; Vol. 36 (20), pp. 2105-2122. Date of Electronic Publication: 2018 May 30.
Typ publikacji :
Journal Article; Practice Guideline
MeSH Terms :
Breast Neoplasms/*enzymology
Receptor, ErbB-2/*analysis
Biopsy ; Breast Neoplasms/pathology ; Humans ; Immunohistochemistry/methods ; Immunohistochemistry/standards
Czasopismo naukowe
Tytuł :
Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study.
Autorzy :
Filipits M; Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. .
Dafni U; Frontier Science Foundation-Hellas, Zografou, and National and Kapodistrian University of Athens, Athens, Greece.
Gnant M; Department of Surgery, Medical University of Vienna, Comprehensive Cancer Center, Vienna, Austria.
Polydoropoulou V; Frontier Science Foundation-Hellas, Zografou, and National and Kapodistrian University of Athens, Athens, Greece.
Hills M; The Royal Marsden Hospital, London, United Kingdom.
Kiermaier A; Oncology Biomarker Development, Genentech, Basel, Switzerland.
de Azambuja E; Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Larsimont D; Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Rojo F; Pathology Department, University Hospital 'Fundacion Jimenez Diaz,' Madrid, Spain.
Viale G; University of Milan, European Institute of Oncology, Milan, Italy.
Toi M; Department of Surgery, Kyoto University, Kyoto, Japan.
Harbeck N; Breast Center, University of Munich (LMU), Munich, Germany.
Prichard KI; Sunnybrook Odette Cancer Centre, Toronto Sunnybrook Regional Cancer Centre, Toronto, Canada.
Gelber RD; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard TH Chan School of Public Health and Frontier Science and Technology Research Foundation, Boston, Massachusetts.
Dinh P; Westmead Hospital, University of Sydney, Sydney, Australia.
Zardavas D; Breast International Group (BIG), Brussels, Belgium.
Leyland-Jones B; Avera Cancer Institute, Sioux Falls, South Dakota.
Piccart-Gebhart MJ; Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium.; Breast International Group (BIG), Brussels, Belgium.
Dowsett M
Pokaż więcej
Corporate Authors :
TransHERA investigators
Źródło :
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2018 Jul 01; Vol. 24 (13), pp. 3079-3086. Date of Electronic Publication: 2018 Mar 12.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Breast Neoplasms/*drug therapy
Breast Neoplasms/*genetics
Cyclin D1/*genetics
Cyclin-Dependent Kinase Inhibitor p27/*genetics
Gene Expression Regulation, Neoplastic/*drug effects
Receptor, ErbB-2/*genetics
Trastuzumab/*therapeutic use
Adult ; Aged ; Antineoplastic Agents, Immunological/therapeutic use ; Biomarkers, Tumor ; Breast Neoplasms/diagnosis ; Breast Neoplasms/mortality ; Chemotherapy, Adjuvant ; Cyclin D1/metabolism ; Cyclin-Dependent Kinase Inhibitor p27/metabolism ; Female ; Humans ; Middle Aged ; Neoplasm Grading ; Neoplasm Metastasis ; Neoplasm Staging ; Prognosis ; Receptor, ErbB-2/metabolism ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
HER2 Status in Gastric and Gastroesophageal Junction Cancer: Results of the Large, Multinational HER-EAGLE Study.
Autorzy :
Kim WH; Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.
Gomez-Izquierdo L; Department of Anatomical Pathology, Hospital Universitario Virgen del Rocio, Seville, Spain.
Vilardell F; Anatomical Pathology Service, Hospital Universitari Arnau de Vilanova de Lleida and IRBLleida, Lleida, Spain.
Chu KM; Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
Soucy G; Pathology Department, Hôpital Saint-Luc du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
Dos Santos LV; Instituto de Ensino e Pesquisa São Lucas and Clinical Research Unit, Barretos Cancer Hospital, São Paulo, Brazil.
Monges G; Department of Pathology, Centre Hospitalier Universitaire de Nice, Hôpital Pasteur, Nice, France.
Viale G; Department of Pathology, European Institute of Oncology, University of Milan, Milan, Italy.
Brito MJ; Department of Pathology, Hospital Garcia de Orta, Almada, Portugal.
Osborne S; GMA Biometrics, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Noé J; Oncology Biomarker Development, Genentech, Basel, Switzerland.
Du X; Department of Pathology, Cancer Center of Fudan University and Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Pokaż więcej
Źródło :
Applied immunohistochemistry & molecular morphology : AIMM [Appl Immunohistochem Mol Morphol] 2018 Apr; Vol. 26 (4), pp. 239-245.
Typ publikacji :
Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Age Factors*
Esophageal Neoplasms/*metabolism
Esophagogastric Junction/*pathology
Receptor, ErbB-2/*metabolism
Stomach Neoplasms/*metabolism
Aged ; Asia/epidemiology ; Brazil/epidemiology ; Canada/epidemiology ; Early Detection of Cancer ; Esophageal Neoplasms/epidemiology ; Europe/epidemiology ; Female ; Humans ; Immunohistochemistry ; International Cooperation ; Male ; Middle Aged ; Sex Factors ; Stomach Neoplasms/epidemiology
Czasopismo naukowe
Tytuł :
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
Autorzy :
Gianni L; Department of Medical Oncology, San Raffaele Scientific Institute, Milan, Italy. Electronic address: .
Bisagni G; IRCCS Arcispedale S Maria Nuova Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Italy.
Colleoni M; European Institute of Oncology, Milan, Italy.
Del Mastro L; Department of Medical Oncology, IRCCS Azienda Ospedaliera Universitaria San Martino-IST, Genoa, Italy.
Zamagni C; SSD Medical Oncology Addari, Policlinico Sant'Orsola Malpighi, Bologna, Italy.
Mansutti M; Department of Oncology, Azienda Sanitaria Universitaria Integrata, Udine, Italy.
Zambetti M; Department of Medical Oncology, San Raffaele Scientific Institute, Milan, Italy.
Frassoldati A; Oncology, Azienda Ospedaliero Universitaria di Ferrara-Arcispedale Sant'Anna, Ferrara, Italy.
De Fato R; Fondazione Michelangelo, Milan, Italy.
Valagussa P; Fondazione Michelangelo, Milan, Italy.
Viale G; European Institute of Oncology, Milan, Italy.
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2018 Feb; Vol. 19 (2), pp. 249-256. Date of Electronic Publication: 2018 Jan 08.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Breast Neoplasms/*drug therapy
Breast Neoplasms/*mortality
Receptor, ErbB-2/*analysis
Receptors, Estrogen/*analysis
Administration, Oral ; Adult ; Aged ; Antibodies, Monoclonal, Humanized/administration & dosage ; Breast Neoplasms/pathology ; Breast Neoplasms/surgery ; Disease-Free Survival ; Female ; Fulvestrant/administration & dosage ; Humans ; Infusions, Intravenous ; Injections, Intramuscular ; Italy ; Kaplan-Meier Estimate ; Middle Aged ; Neoadjuvant Therapy/methods ; Piperazines/administration & dosage ; Prognosis ; Proportional Hazards Models ; Pyridines/administration & dosage ; Response Evaluation Criteria in Solid Tumors ; Survival Analysis ; Trastuzumab/administration & dosage ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Controversies in treatment selection for patients with equivocal ER and HER2 results.
Autorzy :
Viale G; University of Milan, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. Electronic address: giuseppe.viale@ieo.it.
Pokaż więcej
Źródło :
Breast (Edinburgh, Scotland) [Breast] 2017 Aug; Vol. 34 Suppl 1, pp. S61-S63. Date of Electronic Publication: 2017 Jun 27.
Typ publikacji :
Journal Article
MeSH Terms :
Breast Neoplasms/*drug therapy
Breast Neoplasms/*metabolism
Receptor, ErbB-2/*metabolism
Receptors, Estrogen/*metabolism
Antineoplastic Agents, Hormonal/therapeutic use ; Antineoplastic Agents, Immunological/therapeutic use ; Breast Neoplasms/genetics ; Clinical Decision-Making ; Female ; Humans ; Randomized Controlled Trials as Topic ; Receptor, ErbB-2/genetics ; Trastuzumab/therapeutic use
Czasopismo naukowe
Tytuł :
HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.
Autorzy :
Bartlett JMS; Transformative Pathology, Ontario Institute for Cancer Research (OICR), MaRS Centre, 661 University Avenue, Suite 510, Toronto, ON M5G 0A3, Canada; University of Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, The University of Edinburgh, Western General Hospital, Crewe Road South, Edinburgh EH4 2XR, UK. Electronic address: .
Ahmed I; Cancer Research UK Clinical Trials Unit, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. Electronic address: .
Regan MM; International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA. Electronic address: .
Sestak I; Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University, Charterhouse Square, London EC1M 6BQ, UK. Electronic address: .
Mallon EA; Department of Pathology, Elizabeth University Hospital, 1345 Govan Road, Govan, Glasgow G51 4TF, UK. Electronic address: .
Dell'Orto P; Department of Pathology, European Institute of Oncology and University of Milan, Via Giuseppe Ripamonti, 435, 20141 Milan, Italy. Electronic address: .
Thürlimann B; Breast Center, Kantonsspital, St. Gallen, and Swiss Group for Clinical Cancer Research SAKK, CH-9007 St. Gallen, Switzerland. Electronic address: .
Seynaeve C; Department of Medical Oncology, Erasmus MC Cancer Institute, PO Box 5201, Rotterdam 3008 AE, The Netherlands. Electronic address: .
Putter H; Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands. Electronic address: .
Van de Velde CJH; Division of Surgery, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands. Electronic address: .
Brookes CL; Leicester Clinical Trials Unit, University of Leicester, Leicester LE5 4PW, UK. Electronic address: .
Forbes JF; Surgical Oncology, University of Newcastle, Calvary Mater Newcastle Hospital, Locked Bag 7, HRMC, Newcastle, NSW 2310, Australia. Electronic address: .
Viale G; Department of Pathology, European Institute of Oncology and University of Milan, Via Giuseppe Ripamonti, 435, 20141 Milan, Italy. Electronic address: giuseppe.viale@ieo.it.
Cuzick J; Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University, Charterhouse Square, London EC1M 6BQ, UK. Electronic address: .
Dowsett M; Academic Department of Biochemistry, Royal Marsden Hospital, and Endocrinology, Breakthrough Breast Cancer Centre, Institute of Cancer Research, Fulham Road, London SW3 6JJ, UK. Electronic address: .
Rea DW; Cancer Research UK Clinical Trials Unit, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. Electronic address: .
Pokaż więcej
Corporate Authors :
Translational Aromatase Inhibitor Overview Group (Trans-AIOG)
Źródło :
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2017 Jul; Vol. 79, pp. 129-138. Date of Electronic Publication: 2017 May 08.
Typ publikacji :
Journal Article; Meta-Analysis
MeSH Terms :
Antineoplastic Agents, Hormonal/*therapeutic use
Aromatase Inhibitors/*therapeutic use
Breast Neoplasms/*drug therapy
Receptor, ErbB-2/*metabolism
Aged ; Anastrozole ; Breast Neoplasms/metabolism ; Breast Neoplasms/surgery ; Chemotherapy, Adjuvant/methods ; Clinical Trials, Phase III as Topic ; Drug Substitution ; Female ; Humans ; Mastectomy/statistics & numerical data ; Middle Aged ; Multicenter Studies as Topic ; Nitriles/therapeutic use ; Prospective Studies ; Randomized Controlled Trials as Topic ; Receptors, Estrogen/metabolism ; Receptors, Progesterone/metabolism ; Tamoxifen/therapeutic use ; Treatment Outcome ; Triazoles/therapeutic use
Czasopismo naukowe
Tytuł :
An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®.
Autorzy :
Varga Z; Institute of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland. .
Lebeau A; Private Group Practice for Pathology and PathoPlan GbR, Lübeck, Germany.
Bu H; Department of Pathology and Laboratory of Pathology, West China Hospital, Sichuan University, Chengdu, China.
Hartmann A; Institute of Pathology, University Erlangen-Nürnberg, Erlangen, Germany.
Penault-Llorca F; Centre Jean Perrin, Centre regional de Lutte contre le cancer d'Auvergne, Clermont-Ferrand, France.
Guerini-Rocco E; European Institute of Oncology, University of Milan, Milan, Italy.
Schraml P; Institute of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.
Symmans F; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Stoehr R; Institute of Pathology, University Erlangen-Nürnberg, Erlangen, Germany.
Teng X; Department of Pathology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Turzynski A; Private Group Practice for Pathology and PathoPlan GbR, Lübeck, Germany.
von Wasielewski R; Institute of Pathology, Klinikum Region Hannover, Hannover, Germany.
Gürtler C; BioNTech Diagnostics GmbH, Mainz, Germany.
Laible M; BioNTech Diagnostics GmbH, Mainz, Germany.
Schlombs K; BioNTech Diagnostics GmbH, Mainz, Germany.
Joensuu H; Department of Oncology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Keller T; ACOMED Statistik, Leipzig, Germany.
Sinn P; Department of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Sahin U; BioNTech Diagnostics GmbH, Mainz, Germany.
Bartlett J; Transformative Pathology, Ontario Institute for Cancer Research (OICR), Toronto, ON, Canada.
Viale G; European Institute of Oncology, University of Milan, Milan, Italy.
Pokaż więcej
Źródło :
Breast cancer research : BCR [Breast Cancer Res] 2017 May 11; Vol. 19 (1), pp. 55. Date of Electronic Publication: 2017 May 11.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Breast Neoplasms/*diagnosis
Estrogen Receptor alpha/*genetics
Intracellular Signaling Peptides and Proteins/*genetics
Ki-67 Antigen/*genetics
Nuclear Proteins/*genetics
Receptor, ErbB-2/*genetics
Biomarkers, Tumor/genetics ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Female ; Formaldehyde ; Gene Expression Regulation, Neoplastic/genetics ; Humans ; Prognosis ; Prospective Studies ; RNA, Messenger/genetics
Czasopismo naukowe
Tytuł :
Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment.
Autorzy :
Orlando L; Medical Oncology Division & Breast Unit, 72100 Brindisi, Italy. Electronic address: .
Viale G; Pathology Division, European Institute of Oncology, University of Milan, 20141 Milan, Italy.
Bria E; Medical Oncology & Breast Unit, University of Verona, Azienda Ospedaliera Universitaria Integrata, 37134 Verona, Italy.
Lutrino ES; Medical Oncology Division & Breast Unit, 72100 Brindisi, Italy.
Sperduti I; Biostatistics, Regina Elena National Cancer Institute, 00144 Rome, Italy.
Carbognin L; Medical Oncology & Breast Unit, University of Verona, Azienda Ospedaliera Universitaria Integrata, 37134 Verona, Italy.
Schiavone P; Medical Oncology Division & Breast Unit, 72100 Brindisi, Italy.
Quaranta A; Medical Oncology Division & Breast Unit, 72100 Brindisi, Italy.
Fedele P; Medical Oncology Division & Breast Unit, 72100 Brindisi, Italy.
Caliolo C; Medical Oncology Division & Breast Unit, 72100 Brindisi, Italy.
Calvani N; Medical Oncology Division & Breast Unit, 72100 Brindisi, Italy.
Criscuolo M; Medical Oncology Division & Breast Unit, 72100 Brindisi, Italy.
Cinieri S; Medical Oncology Division & Breast Unit, 72100 Brindisi, Italy.
Pokaż więcej
Źródło :
Breast (Edinburgh, Scotland) [Breast] 2016 Dec; Vol. 30, pp. 151-155. Date of Electronic Publication: 2016 Oct 14.
Typ publikacji :
Journal Article
MeSH Terms :
Breast Neoplasms/*metabolism
Carcinoma, Ductal, Breast/*metabolism
Carcinoma, Lobular/*metabolism
Ki-67 Antigen/*metabolism
Receptor, ErbB-2/*metabolism
Receptors, Estrogen/*metabolism
Receptors, Progesterone/*metabolism
Adult ; Aged ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents, Hormonal/therapeutic use ; Breast Neoplasms/drug therapy ; Breast Neoplasms/pathology ; Carcinoma, Ductal, Breast/drug therapy ; Carcinoma, Ductal, Breast/pathology ; Carcinoma, Lobular/drug therapy ; Carcinoma, Lobular/pathology ; Chemotherapy, Adjuvant ; Female ; Humans ; Immunohistochemistry ; Middle Aged ; Neoplasm Grading ; Observer Variation ; Pathology, Clinical ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Analysis of HER2 status in gastroesophageal tumor specimens using a new automated HER2 IQFISH pharmDx™ (Dako Omnis) assay.
Autorzy :
Viale G; University of Milan, Istituto Europeo di Oncologia, Milan, Italy.
Paterson J; UCL Advanced Diagnostics, London, UK.
Bloch M; Clarient Pathology Services, Aliso Viejo, CA, USA.
Csathy G; Clarient Pathology Services, Aliso Viejo, CA, USA.
Allen D; UCL Advanced Diagnostics, London, UK.
Dell'Orto P; University of Milan, Istituto Europeo di Oncologia, Milan, Italy.
Kjærsgaard G; Dako, An Agilent Technologies Company, Glostrup, Denmark.
Levy YY; Dako, An Agilent Technologies Company, Glostrup, Denmark.
Jørgensen JT; Dx-Rx Institute, Fredensborg, Denmark. .
Pokaż więcej
Źródło :
Histology and histopathology [Histol Histopathol] 2016 Dec; Vol. 31 (12), pp. 1327-35. Date of Electronic Publication: 2016 Mar 18.
Typ publikacji :
Journal Article
MeSH Terms :
Esophagogastric Junction/*pathology
Gene Expression Profiling/*methods
In Situ Hybridization, Fluorescence/*methods
Receptor, ErbB-2/*analysis
Stomach Neoplasms/*pathology
Biomarkers, Tumor/analysis ; Humans ; Observer Variation ; Reproducibility of Results
Czasopismo naukowe
Tytuł :
Assessment of HER2 amplification status in breast cancer using a new automated HER2 IQFISH pharmDx™ (Dako Omnis) assay.
Autorzy :
Viale G; University of Milan, Istituto Europeo di Oncologia, Milan, Italy.
Paterson J; UCL Advanced Diagnostics, London, UK.
Bloch M; Clarient Pathology Services, Aliso Viejo, CA, USA.
Csathy G; Clarient Pathology Services, Aliso Viejo, CA, USA.
Allen D; UCL Advanced Diagnostics, London, UK.
Dell'Orto P; University of Milan, Istituto Europeo di Oncologia, Milan, Italy.
Kjærsgaard G; Dako, An Agilent Technologies Company, Glostrup, Denmark.
Levy YY; Dako, An Agilent Technologies Company, Glostrup, Denmark.
Jørgensen JT; Dx-Rx Institute, Baunevaenget 76, DK-3480 Fredensborg, Denmark. Electronic address: .
Pokaż więcej
Źródło :
Pathology, research and practice [Pathol Res Pract] 2016 Aug; Vol. 212 (8), pp. 735-42. Date of Electronic Publication: 2016 Jun 08.
Typ publikacji :
Journal Article; Validation Study
MeSH Terms :
Gene Amplification*
Breast Neoplasms/*diagnosis
Breast Neoplasms/*genetics
In Situ Hybridization, Fluorescence/*standards
Receptor, ErbB-2/*genetics
Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Female ; Humans ; In Situ Hybridization, Fluorescence/methods ; Receptor, ErbB-2/metabolism ; Reproducibility of Results
Czasopismo naukowe
Tytuł :
Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
Autorzy :
Loi S; Division of Research and Clinical Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
Dafni U; Frontier Science Foundation- Hellas, Athens, Greece3University of Athens, Athens, Greece.
Karlis D; Frontier Science Foundation- Hellas, Athens, Greece4Athens University of Economics and Business, Athens, Greece.
Polydoropoulou V; Frontier Science Foundation- Hellas, Athens, Greece.
Young BM; Avera Cancer Institute, Department of Molecular and Experimental Medicine, Sioux Falls, South Dakota.
Willis S; Avera Cancer Institute, Department of Molecular and Experimental Medicine, Sioux Falls, South Dakota.
Long B; Department of Pathology, University of Chicago, Chicago, Illinois.
de Azambuja E; BREAST Datacentre, Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium.
Sotiriou C; Breast Cancer Translational Research Laboratory, Institute Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium.
Viale G; University of Milan, European Institute of Oncology, Milan, Italy.
Rüschoff J; Targos Molecular Pathology GmbH, Kassel, Germany.
Piccart MJ; Department of Medicine, Institute Jules Bordet, Universite Libre de Bruxelles and Breast International Group (BIG), Brussels, Belgium12Breast International Group (BIG), Brussels, Belgium.
Dowsett M; Royal Marsden Hospital, London, England.
Michiels S; INSERM U1018 CESP, Service de Biostatistique et d'Epidémiologie, Villejuif, France.
Leyland-Jones B; Avera Cancer Institute, Department of Molecular and Experimental Medicine, Sioux Falls, South Dakota.
Pokaż więcej
Źródło :
JAMA oncology [JAMA Oncol] 2016 Aug 01; Vol. 2 (8), pp. 1040-7.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Breast Neoplasms/*metabolism
Carcinoma/*metabolism
Estrogen Receptor alpha/*metabolism
RNA, Messenger/*metabolism
Receptor, ErbB-2/*metabolism
Trastuzumab/*therapeutic use
Adult ; Breast Neoplasms/drug therapy ; Carcinoma/drug therapy ; Chemotherapy, Adjuvant ; Disease-Free Survival ; Estrogen Receptor alpha/genetics ; Female ; Humans ; Immunohistochemistry ; In Situ Hybridization, Fluorescence ; Middle Aged ; Multivariate Analysis ; Prognosis ; Proportional Hazards Models ; Randomized Controlled Trials as Topic ; Receptor, ErbB-2/genetics
Czasopismo naukowe
Tytuł :
Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.
Autorzy :
Regan MM; Meredith M. Regan and Richard D. Gelber, Dana-Farber Cancer Institute, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Prudence A. Francis, MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, Australia; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello, Switzerland; Gini F. Fleming, University of Chicago Medical Center, Chicago, IL; Barbara A. Walley, National Cancer Institute of Canada Clinical Trials Group, Calgary, Alberta, Canada; Giuseppe Viale, University of Milan; Giuseppe Viale, Marco Colleoni, and Aron Goldhirsch, European Institute of Oncology, Milan; Carlo Tondini, Ospedale Papa Giovanni XXIII, Bergamo; Graziella Pinotti, Ospedale di Circolo and Fondazione Macchi, Varese, Italy; István Láng, National Institute of Oncology, Budapest, Hungary; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásticas, Lima, Peru. .
Francis PA; Meredith M. Regan and Richard D. Gelber, Dana-Farber Cancer Institute, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Prudence A. Francis, MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, Australia; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello, Switzerland; Gini F. Fleming, University of Chicago Medical Center, Chicago, IL; Barbara A. Walley, National Cancer Institute of Canada Clinical Trials Group, Calgary, Alberta, Canada; Giuseppe Viale, University of Milan; Giuseppe Viale, Marco Colleoni, and Aron Goldhirsch, European Institute of Oncology, Milan; Carlo Tondini, Ospedale Papa Giovanni XXIII, Bergamo; Graziella Pinotti, Ospedale di Circolo and Fondazione Macchi, Varese, Italy; István Láng, National Institute of Oncology, Budapest, Hungary; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásticas, Lima, Peru.
Pagani O; Meredith M. Regan and Richard D. Gelber, Dana-Farber Cancer Institute, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Prudence A. Francis, MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, Australia; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello, Switzerland; Gini F. Fleming, University of Chicago Medical Center, Chicago, IL; Barbara A. Walley, National Cancer Institute of Canada Clinical Trials Group, Calgary, Alberta, Canada; Giuseppe Viale, University of Milan; Giuseppe Viale, Marco Colleoni, and Aron Goldhirsch, European Institute of Oncology, Milan; Carlo Tondini, Ospedale Papa Giovanni XXIII, Bergamo; Graziella Pinotti, Ospedale di Circolo and Fondazione Macchi, Varese, Italy; István Láng, National Institute of Oncology, Budapest, Hungary; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásticas, Lima, Peru.
Fleming GF; Meredith M. Regan and Richard D. Gelber, Dana-Farber Cancer Institute, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Prudence A. Francis, MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, Australia; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello, Switzerland; Gini F. Fleming, University of Chicago Medical Center, Chicago, IL; Barbara A. Walley, National Cancer Institute of Canada Clinical Trials Group, Calgary, Alberta, Canada; Giuseppe Viale, University of Milan; Giuseppe Viale, Marco Colleoni, and Aron Goldhirsch, European Institute of Oncology, Milan; Carlo Tondini, Ospedale Papa Giovanni XXIII, Bergamo; Graziella Pinotti, Ospedale di Circolo and Fondazione Macchi, Varese, Italy; István Láng, National Institute of Oncology, Budapest, Hungary; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásticas, Lima, Peru.
Walley BA; Meredith M. Regan and Richard D. Gelber, Dana-Farber Cancer Institute, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Prudence A. Francis, MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, Australia; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello, Switzerland; Gini F. Fleming, University of Chicago Medical Center, Chicago, IL; Barbara A. Walley, National Cancer Institute of Canada Clinical Trials Group, Calgary, Alberta, Canada; Giuseppe Viale, University of Milan; Giuseppe Viale, Marco Colleoni, and Aron Goldhirsch, European Institute of Oncology, Milan; Carlo Tondini, Ospedale Papa Giovanni XXIII, Bergamo; Graziella Pinotti, Ospedale di Circolo and Fondazione Macchi, Varese, Italy; István Láng, National Institute of Oncology, Budapest, Hungary; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásticas, Lima, Peru.
Viale G; Meredith M. Regan and Richard D. Gelber, Dana-Farber Cancer Institute, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Prudence A. Francis, MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, Australia; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello, Switzerland; Gini F. Fleming, University of Chicago Medical Center, Chicago, IL; Barbara A. Walley, National Cancer Institute of Canada Clinical Trials Group, Calgary, Alberta, Canada; Giuseppe Viale, University of Milan; Giuseppe Viale, Marco Colleoni, and Aron Goldhirsch, European Institute of Oncology, Milan; Carlo Tondini, Ospedale Papa Giovanni XXIII, Bergamo; Graziella Pinotti, Ospedale di Circolo and Fondazione Macchi, Varese, Italy; István Láng, National Institute of Oncology, Budapest, Hungary; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásticas, Lima, Peru.
Colleoni M; Meredith M. Regan and Richard D. Gelber, Dana-Farber Cancer Institute, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Prudence A. Francis, MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, Australia; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello, Switzerland; Gini F. Fleming, University of Chicago Medical Center, Chicago, IL; Barbara A. Walley, National Cancer Institute of Canada Clinical Trials Group, Calgary, Alberta, Canada; Giuseppe Viale, University of Milan; Giuseppe Viale, Marco Colleoni, and Aron Goldhirsch, European Institute of Oncology, Milan; Carlo Tondini, Ospedale Papa Giovanni XXIII, Bergamo; Graziella Pinotti, Ospedale di Circolo and Fondazione Macchi, Varese, Italy; István Láng, National Institute of Oncology, Budapest, Hungary; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásticas, Lima, Peru.
Láng I; Meredith M. Regan and Richard D. Gelber, Dana-Farber Cancer Institute, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Prudence A. Francis, MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, Australia; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello, Switzerland; Gini F. Fleming, University of Chicago Medical Center, Chicago, IL; Barbara A. Walley, National Cancer Institute of Canada Clinical Trials Group, Calgary, Alberta, Canada; Giuseppe Viale, University of Milan; Giuseppe Viale, Marco Colleoni, and Aron Goldhirsch, European Institute of Oncology, Milan; Carlo Tondini, Ospedale Papa Giovanni XXIII, Bergamo; Graziella Pinotti, Ospedale di Circolo and Fondazione Macchi, Varese, Italy; István Láng, National Institute of Oncology, Budapest, Hungary; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásticas, Lima, Peru.
Gómez HL; Meredith M. Regan and Richard D. Gelber, Dana-Farber Cancer Institute, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Prudence A. Francis, MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, Australia; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello, Switzerland; Gini F. Fleming, University of Chicago Medical Center, Chicago, IL; Barbara A. Walley, National Cancer Institute of Canada Clinical Trials Group, Calgary, Alberta, Canada; Giuseppe Viale, University of Milan; Giuseppe Viale, Marco Colleoni, and Aron Goldhirsch, European Institute of Oncology, Milan; Carlo Tondini, Ospedale Papa Giovanni XXIII, Bergamo; Graziella Pinotti, Ospedale di Circolo and Fondazione Macchi, Varese, Italy; István Láng, National Institute of Oncology, Budapest, Hungary; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásticas, Lima, Peru.
Tondini C; Meredith M. Regan and Richard D. Gelber, Dana-Farber Cancer Institute, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Prudence A. Francis, MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, Australia; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello, Switzerland; Gini F. Fleming, University of Chicago Medical Center, Chicago, IL; Barbara A. Walley, National Cancer Institute of Canada Clinical Trials Group, Calgary, Alberta, Canada; Giuseppe Viale, University of Milan; Giuseppe Viale, Marco Colleoni, and Aron Goldhirsch, European Institute of Oncology, Milan; Carlo Tondini, Ospedale Papa Giovanni XXIII, Bergamo; Graziella Pinotti, Ospedale di Circolo and Fondazione Macchi, Varese, Italy; István Láng, National Institute of Oncology, Budapest, Hungary; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásticas, Lima, Peru.
Pinotti G; Meredith M. Regan and Richard D. Gelber, Dana-Farber Cancer Institute, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Prudence A. Francis, MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, Australia; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello, Switzerland; Gini F. Fleming, University of Chicago Medical Center, Chicago, IL; Barbara A. Walley, National Cancer Institute of Canada Clinical Trials Group, Calgary, Alberta, Canada; Giuseppe Viale, University of Milan; Giuseppe Viale, Marco Colleoni, and Aron Goldhirsch, European Institute of Oncology, Milan; Carlo Tondini, Ospedale Papa Giovanni XXIII, Bergamo; Graziella Pinotti, Ospedale di Circolo and Fondazione Macchi, Varese, Italy; István Láng, National Institute of Oncology, Budapest, Hungary; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásticas, Lima, Peru.
Price KN; Meredith M. Regan and Richard D. Gelber, Dana-Farber Cancer Institute, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Prudence A. Francis, MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, Australia; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello, Switzerland; Gini F. Fleming, University of Chicago Medical Center, Chicago, IL; Barbara A. Walley, National Cancer Institute of Canada Clinical Trials Group, Calgary, Alberta, Canada; Giuseppe Viale, University of Milan; Giuseppe Viale, Marco Colleoni, and Aron Goldhirsch, European Institute of Oncology, Milan; Carlo Tondini, Ospedale Papa Giovanni XXIII, Bergamo; Graziella Pinotti, Ospedale di Circolo and Fondazione Macchi, Varese, Italy; István Láng, National Institute of Oncology, Budapest, Hungary; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásticas, Lima, Peru.
Coates AS; Meredith M. Regan and Richard D. Gelber, Dana-Farber Cancer Institute, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Prudence A. Francis, MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, Australia; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello, Switzerland; Gini F. Fleming, University of Chicago Medical Center, Chicago, IL; Barbara A. Walley, National Cancer Institute of Canada Clinical Trials Group, Calgary, Alberta, Canada; Giuseppe Viale, University of Milan; Giuseppe Viale, Marco Colleoni, and Aron Goldhirsch, European Institute of Oncology, Milan; Carlo Tondini, Ospedale Papa Giovanni XXIII, Bergamo; Graziella Pinotti, Ospedale di Circolo and Fondazione Macchi, Varese, Italy; István Láng, National Institute of Oncology, Budapest, Hungary; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásticas, Lima, Peru.
Goldhirsch A; Meredith M. Regan and Richard D. Gelber, Dana-Farber Cancer Institute, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Prudence A. Francis, MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, Australia; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello, Switzerland; Gini F. Fleming, University of Chicago Medical Center, Chicago, IL; Barbara A. Walley, National Cancer Institute of Canada Clinical Trials Group, Calgary, Alberta, Canada; Giuseppe Viale, University of Milan; Giuseppe Viale, Marco Colleoni, and Aron Goldhirsch, European Institute of Oncology, Milan; Carlo Tondini, Ospedale Papa Giovanni XXIII, Bergamo; Graziella Pinotti, Ospedale di Circolo and Fondazione Macchi, Varese, Italy; István Láng, National Institute of Oncology, Budapest, Hungary; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásticas, Lima, Peru.
Gelber RD; Meredith M. Regan and Richard D. Gelber, Dana-Farber Cancer Institute, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Prudence A. Francis, MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, Australia; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello, Switzerland; Gini F. Fleming, University of Chicago Medical Center, Chicago, IL; Barbara A. Walley, National Cancer Institute of Canada Clinical Trials Group, Calgary, Alberta, Canada; Giuseppe Viale, University of Milan; Giuseppe Viale, Marco Colleoni, and Aron Goldhirsch, European Institute of Oncology, Milan; Carlo Tondini, Ospedale Papa Giovanni XXIII, Bergamo; Graziella Pinotti, Ospedale di Circolo and Fondazione Macchi, Varese, Italy; István Láng, National Institute of Oncology, Budapest, Hungary; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásticas, Lima, Peru.
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2016 Jul 01; Vol. 34 (19), pp. 2221-31. Date of Electronic Publication: 2016 Apr 04.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Androstadienes/*administration & dosage
Breast Neoplasms/*drug therapy
Receptor, ErbB-2/*analysis
Receptors, Estrogen/*analysis
Tamoxifen/*administration & dosage
Adult ; Aged ; Breast Neoplasms/chemistry ; Clinical Trials as Topic ; Female ; Humans ; Middle Aged ; Neoplasm Recurrence, Local ; Ovary/physiopathology ; Proportional Hazards Models
Czasopismo naukowe
Tytuł :
HER2 Equivocal Status in Early Breast Cancer Is Not Associated with Higher Risk of Recurrence.
Autorzy :
Criscitiello C; Division of Experimental Therapeutics, University of Milan-Bicocca, Milan, Italy.
Bagnardi V; Division of Epidemiology and Biostatistics, University of Milan-Bicocca, Milan, Italy Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy.
Viale G; Department of Pathology, School of Medicine, University of Milan, Milan, Italy.
Disalvatore D; Division of Epidemiology and Biostatistics, University of Milan-Bicocca, Milan, Italy.
Rotmensz N; Division of Experimental Therapeutics, University of Milan-Bicocca, Milan, Italy.
Esposito A; Division of Experimental Therapeutics, University of Milan-Bicocca, Milan, Italy.
Goldhirsch A; Breast Health Program, European Institute of Oncology, Milan, Italy.
Curigliano G; Division of Experimental Therapeutics, University of Milan-Bicocca, Milan, Italy giuseppe..
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2016 Jul; Vol. 36 (7), pp. 3537-40.
Typ publikacji :
Journal Article
MeSH Terms :
Breast Neoplasms/*metabolism
Neoplasm Recurrence, Local/*metabolism
Receptor, ErbB-2/*metabolism
Adult ; Aged ; Breast Neoplasms/mortality ; Breast Neoplasms/pathology ; Disease-Free Survival ; Female ; Gene Expression ; Humans ; Middle Aged ; Neoplasm Recurrence, Local/mortality ; Prognosis ; Proportional Hazards Models ; Receptor, ErbB-2/genetics ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.
Autorzy :
Piccart-Gebhart M; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Holmes E; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Baselga J; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
de Azambuja E; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Dueck AC; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Viale G; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Zujewski JA; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Goldhirsch A; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Armour A; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Pritchard KI; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
McCullough AE; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Dolci S; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
McFadden E; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Holmes AP; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Tonghua L; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Eidtmann H; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Dinh P; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Di Cosimo S; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Harbeck N; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Tjulandin S; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Im YH; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Huang CS; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Diéras V; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Hillman DW; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Wolff AC; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Jackisch C; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Lang I; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Untch M; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Smith I; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Boyle F; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Xu B; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Gomez H; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Suter T; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Gelber RD; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Perez EA; Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2016 Apr 01; Vol. 34 (10), pp. 1034-42. Date of Electronic Publication: 2015 Nov 23.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
MeSH Terms :
Antineoplastic Agents/*administration & dosage
Antineoplastic Agents/*adverse effects
Biomarkers, Tumor/*analysis
Breast Neoplasms/*drug therapy
Quinazolines/*administration & dosage
Quinazolines/*adverse effects
Receptor, ErbB-2/*analysis
Trastuzumab/*administration & dosage
Trastuzumab/*adverse effects
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Breast Neoplasms/chemistry ; Breast Neoplasms/pathology ; Chemotherapy, Adjuvant ; Drug Administration Schedule ; Female ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Lapatinib ; Middle Aged ; Neoplasm Staging ; Patient Selection ; Treatment Outcome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies